Figure 2.Association between CHRDL1 expression and clinicopathologic characteristics, including (A–H): T stage (P<0.001), N stage (P=0.003), Pathologic stage (P=0.003), Tumor status (P=0.006), Primary therapy outcome (P=0.030), TP53 status (P<0.001), Gender (P<0.001) and Age (P<0.001) in patients with LUAD in a TCGA cohort.
